Clearmind Medicine

Company Overview

Snapshot

Founded in January 2021, Clearmind Medicine is a public company with 1–10 employees. The company has raised $16.21M across 6 funding rounds. In November 2025, Clearmind Medicine announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder.

Business overview

Clearmind Medicine is a Health Tech & Life Sciences company focused on developing treatments for binge behavior and mental health conditions, including alcohol use disorder, binge eating, and depression. Its core product, MEAI, is designed to provide a euphoric alcohol-like experience while reducing the desire to consume alcoholic beverages, aiming to support individuals struggling with moderation. The company operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, leveraging biological molecules for therapeutic applications.

Strategic signal

In September 2024, Clearmind Medicine announced the publication of an international patent application for an innovative MDMA-based combination treatment, following a collaboration with SciSparc. This development signals the company's continued innovation in psychedelic-derived therapies and its strategic focus on expanding its intellectual property portfolio for novel mental health treatments, indicating a forward trajectory in drug discovery and development.

Company Intelligence Q&A

What was a significant recent development in Clearmind Medicine's clinical trials for Alcohol Use Disorder?

In November 2025, Clearmind Medicine announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder. This milestone indicates progress in the clinical development of its CMND-100 treatment.

What recent patent application did Clearmind Medicine publish?

In September 2024, Clearmind Medicine announced the publication of an international patent application for an innovative MDMA-based combination treatment. This was a result of its collaboration with SciSparc.

What was the outcome of the Data and Safety Monitoring Board review for Clearmind Medicine's CMND-100 clinical trial?

In November 2025, Clearmind Medicine's Data and Safety Monitoring Board unanimously approved the continuation of the Phase I/IIa clinical trial for CMND-100, following a positive interim safety review.

What strategic partnership did Clearmind Medicine establish with Johns Hopkins University?

In September 2023, Clearmind Medicine announced a clinical research collaboration with Johns Hopkins University to evaluate CMND-100 in patients with Alcohol Use Disorder, aiming to advance its research in this area.

What was a key development regarding Clearmind Medicine's intellectual property for depression treatment?

In November 2025, Clearmind Medicine expanded its global IP protection for MEAI in depression treatment with a new South Korea patent filing, indicating its efforts to secure its non-hallucinogenic neuroplastogen therapy in international markets.